ClinicalTrials.gg
Not yet recruitingNCT07735208ALIGN-AMLUpdated Jul 29, 2026

Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia

A Phase 2 interventional study of GA-directed treatment regimens in Acute Myeloid Leukemia, sponsored by University of Rochester. Not yet recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by University of Rochester · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Leukemia, Myeloid, Acute by University of Rochester — 5 open to participants now, 5 under way, none of them phase 3. Leukemia, Myeloid, Acute · University of Rochester.

Planned enrollment
4th of 12
120 · median 26
Started
2026
with 1 other
Phase 2
2 of 14
2 open now
Registered
14th of 14
by date

Among the 14 studies in Leukemia, Myeloid, Acute by University of Rochester, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 2, and was the 14th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

5 of the 14 studies in Leukemia, Myeloid, Acute by University of Rochester are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Leukemia, Myeloid, Acute by University of Rochester, or all of them as a file.
02

Study summary

This is a phase 2 randomized controlled trial to evaluate whether a geriatric assessment (GA)-guided treatment strategy reduces treatment-related toxicity and improves patient-centered outcomes compared with usual oncologist-directed care in adults aged 60 years and older with newly diagnosed AML.

Read the detailed description

Acute myeloid leukemia (AML) primarily affects older adults, yet treatment decision-making in this population remains largely inconsistent. Older adults with AML are highly heterogeneous with respect to physiologic reserve, functional status, cognition, and comorbidities, all of which strongly influence treatment tolerance and outcomes. Despite this heterogeneity, treatment decisions are often made rapidly and rely heavily on chronological age and clinician judgment, approaches that have been repeatedly shown to inadequately predict toxicity, early mortality, and functional decline. The proposed trial addresses a critical scientific question: whether a structured geriatric assessment (GA)-guided treatment strategy improves clinically meaningful outcomes compared with usual oncologist-directed care in older adults with AML. Although GA has been extensively validated as a prognostic and risk stratification tool in oncology and has improved care delivery in solid tumors, it has not been tested in a randomized controlled trial in AML, where treatment urgency, toxicity burden, and early adverse events are especially pronounced. This study therefore fills a major evidence gap at the intersection of geriatric oncology and hematologic malignancies.

This multicenter, prospective, randomized controlled trial is designed to evaluate whether a geriatric assessment (GA)-guided treatment strategy improves clinically meaningful outcomes compared with usual oncologist-directed care in older adults with newly diagnosed acute myeloid leukemia (AML). Approximately 120 adults aged 60 years and older will be enrolled across 3 academic and community institutions affiliated with the Cancer and Aging Research Group (CARG). Patients will be randomized in a 1:1 ratio to either a GA-guided treatment arm or a usual-care arm, with randomization stratified by study site and GA-defined fitness category (fit, vulnerable, frail). All patients will undergo a structured GA using the Practical Geriatric Assessment recommended by the American Society of Clinical Oncology and adapted for hematologic malignancies. However, GA results will be used to guide treatment selection only for participants assigned to the intervention arm.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • AML
  • Geriatric Assessment
  • Acute myeloid leukemia
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 60 and above
  2. A diagnosis of de novo, secondary or treatment-related acute myeloid leukemia (AML), other AML equivalent such as myeloid sarcoma, myelodysplastic syndrome in transformation to AML

    1. AML diagnosis can be based on the World Health Organization (WHO) 2022 criteria or International Consensus Classification (ICC) 2022 criteria
    2. The use of hydroxyurea, cytarabine (up to 1 gm total dose), or leukapheresis for cytoreduction is allowed
    3. Patients with brief exposure to all-trans retinoic acid (ATRA), arsenic trioxide (ATO) or similar product for suspected acute promyelocytic leukemia (APL), who later turn out not to have APL, are eligible
    4. The use of other cancer-directed treatments (e.g., hormonal treatment, targeted treatment, immunotherapy, radiation) other than chemotherapy for other concurrent is allowed
  3. Able to provide

Exclusion criteria

Exclusion Criteria:

  1. Acute promyelocytic leukemia
  2. Unwilling to complete study procedures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    GA-guided treatment Arm

    Participants will undergo a Practical Geriatric Assessment (PGA). Based on specific domains and measures within the PGA, participants will be categorized as fit, vulnerable, or frail and will receive treatment tailored to their physiologic status.

    Drug: GA-directed treatment regimens

  • No intervention
    Usual Care/Control Arm

    Participants will undergo a structured Geriatric Assessment (GA) to determine physiologic fitness using the Practical Geriatric Assessment (PGA) and receive therapy determined by their treating oncologist not based on the GA results.

Interventions

  • DrugGA-directed treatment regimens

    Fit, vulnerable, and frail patients will receive predefined regimens based on their GA results.

06

What researchers measure

Primary outcomes

  1. Treatment failure rate at 3 months

    Treatment failure is defined as the occurrence of any of the following within 3 months after treatment initiation: disease progression or relapse, death from any cause, treatment discontinuation for any reason except logistical reasons, absence of at least one agent in the initial treatment regimen for more than 30 days following the last day of the previous treatment cycle (temporary dose interruptions and cycle delays within the 30 day window are not considered treatment failure events), or initiation of an alternative treatment regimen or addition of an agent because of clinician documented concern for lack of efficacy or disease control.

    Time frame: 3 months after treatment initiation

Secondary outcomes

  1. Treatment failure rate at 6 months

    Treatment failure will be assessed at 6 months (180 days) after treatment initiation and include any of the following events: • Disease progression or relapse • Death from any cause • Treatment discontinuation for any reason (except logistical) • Treatment delays, defined as: o Absence of at least one agent in the initial regimen for \>30 days following the last day of prior treatment cycle o Temporary dose interruptions and cycle delays within the 30-day window are not considered treatment failure events • Initiation of an alternative treatment regimen or addition of an agent to the initial regimen due to clinician-documented concern for lack of efficacy or disease control, including but not limited to: o Failure to achieve the expected response o Rising blast percentage or worsening cytopenias attributed to disease o Loss of a prior response

    Time frame: 6 months after treatment initiation

  2. Overall Response Rate

    Best overall response from the initial treatment regimen within the first 6 months after treatment initiation. Overall response includes complete remission (CR), complete remission with incomplete hematologic recovery (CRi), and complete remission with partial hematologic recovery (CRh), assessed according to the European LeukemiaNet (ELN) 2022 response criteria.

    Time frame: 6 months after treatment initiation

  3. Overall survival

    Time from randomization to death from any cause. Participants who are alive at the time of analysis will be censored at the date they were last known to be alive.

    Time frame: Up to 2 years after randomization

  4. Event-free survival

    Time from randomization to the first occurrence of failure to achieve complete remission (CR), complete remission with incomplete hematologic recovery (CRi), or complete remission with partial hematologic recovery (CRh), relapse after achieving CR, CRi, or CRh, or death from any cause.

    Time frame: Up to 2 years after randomization

  5. Grade 3-5 toxicities

    Proportion of participants with Grade 3 or higher nonhematologic adverse events and Grade 3 or higher neutropenia, thrombocytopenia, or anemia associated with the initial treatment regimen, graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Asymptomatic laboratory abnormalities lasting 7 days or less that do not result in a dose modification or treatment hold will not be included.

    Time frame: 6 months after treatment initiation

  6. Unplanned hospitalizations

    Number of unplanned inpatient hospitalizations during the first 6 months after treatment initiation, excluding the initial hospitalization for treatment initiation.

    Time frame: 6 months after treatment initiation

  7. Activities of Daily Living (ADL)

    Change in Katz ADL total score from baseline. ADL measures independence in activities of daily living (including bathing, dressing, toileting, transferring, continence, and feeding). ADL ranges from 0 to 6, with higher scores representing greater independence in activities of daily living.

    Time frame: Collected baseline, start of cycle 2 or consolidation (28 day cycle), day 90

  8. Instrumental Activities of Daily Living (IADL)

    Change in OARS IADL total score from baseline. IADL measures independence in instrumental activities of daily living (including using the telephone, travel, shopping, meal preparation, housework, taking medications, and handling money). IADL ranges from 0 to 14, with higher scores representing greater independence in instrumental activities of daily living.

    Time frame: Collected baseline, start of cycle 2 or consolidation (28 day cycle), day 90

  9. Fall History

    Change in number of falls from baseline. More falls represent worse physical function.

    Time frame: Collected baseline, start of cycle 2 or consolidation (28 day cycle), day 90

  10. Short Physical Performance Battery (SPPB)

    Change in SPPB total score from baseline. SPPB measures physical function and ranges from 0 to 12 (higher scores represent greater physical function).

    Time frame: Collected baseline, start of cycle 2 or consolidation (28 day cycle), day 90

  11. Montreal Cognitive Assessment (MoCA)

    Change in MoCA total score from baseline. MoCA measure cognitive function and ranges from 0 to 30 (higher scores represent greater cognitive function).

    Time frame: Collected baseline, start of cycle 2 or consolidation (28 day cycle), day 90

  12. Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety

    Change in PROMIS Anxiety 4a total score from baseline. PROMIS Anxiety measures anxiety and ranges from 4 to 20 (higher scores represent greater anxiety).

    Time frame: Collected baseline, start of cycle 2 or consolidation (28 day cycle), day 90

  13. Geriatric Depression Scale-15 (GDS-15)

    Change in GDS-15 total score from baseline. GDS-15 measures depression and ranges from 0 to 15 (higher scores represent greater depression).

    Time frame: Collected baseline, start of cycle 2 or consolidation (28 day cycle), day 90

  14. Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu)

    Change in FACT-Leu total score from baseline. FACT-Leu measures quality of life and is designed specifically for patients with leukemia. FACT-Leu ranges from 0 to 176, with higher scores representing better quality of life.

    Time frame: Collected baseline, start of cycle 2 or consolidation (28 day cycle), day 90, day 180, day 360

  15. Patient Reported Toxicities

    Change in patient reported symptomatic toxicities measured using the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO CTCAE). Responses will be assessed longitudinally at the protocol specified assessment time points.

    Time frame: Baseline, during Cycle 1, at the start of Cycle 2 (or consolidation), Day 90, and Day 180. 28 day cycle

07

Study locations

1 site
08

References and documents

Publications

  • Bhatt VR, Wichman CS, Koll TT, Fisher AL, Wildes TM, Haddadin M, Berger AM, Armitage JO, Holstein SA, Maness LJ, Gundabolu K. A Phase II Trial of Geriatric Assessment-Guided Selection of Treatment Intensity in Older Adults With AML. Am J Hematol. 2025 Jul;100(7):1163-1172. doi: 10.1002/ajh.27694. Epub 2025 Apr 29. PubMed 40298352 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Nov 2031, 59 months later.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 59 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 29, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Nov 30, 2031
CompletionEst.
Nov 30, 2031
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07735208
Collaborators
Rising Tide Foundation
Responsible party
Kah Poh Loh (Associate Professor - Department of Medicine, Hematology/Oncology (SMD), University of Rochester) — Principal investigator
First posted
Jul 29, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Nov 30, 2031 (estimated)
Completion
Nov 30, 2031 (estimated)
Last update
Jul 29, 2026

Study contacts

Kah Poh (Melissa) Loh, MD, MS
Contact
Kahpoh_Loh@URMC.Rochester.edu
585-275-5863
Clinical Trials Office
Contact
wcictoresearch@urmc.rochester.edu
585-275-5863

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion